Public Sector Pension Investment Board Makes New Investment in The Chemours Company $CC

Key Points

• The Public Sector Pension Investment Board has made a new investment in The Chemours Company, acquiring 473,839 shares valued at approximately $6.41 million, representing 0.32% of the company's total shares.
• Several institutional investors, including Vanguard and Ameriprise Financial, have increased their stakes in Chemours, indicating strong institutional interest in the specialty chemicals company.
• Analysts have mixed opinions on Chemours, with target prices ranging from $14 to $17; the average rating for the stock is currently "Hold" with a target price of $17.38.

Public Sector Pension Investment Board bought a new position in The Chemours Company (NYSE:CC - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 473,839 shares of the specialty chemicals company's stock, valued at approximately $6,411,000. Public Sector Pension Investment Board owned 0.32% of Chemours as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new position in Chemours during the first quarter worth about $27,000. UMB Bank n.a. raised its stake in Chemours by 73.9% in the first quarter. UMB Bank n.a. now owns 2,231 shares of the specialty chemicals company's stock valued at $30,000 after purchasing an additional 948 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company's stock worth $30,000 after buying an additional 1,444 shares in the last quarter. SouthState Corp bought a new position in shares of Chemours in the 1st quarter worth $34,000. Finally, Itau Unibanco Holding S.A. raised its position in shares of Chemours by 39.3% during the 4th quarter. Itau Unibanco Holding S.A. now owns 3,554 shares of the specialty chemicals company's stock valued at $60,000 after buying an additional 1,003 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors.

Chemours Stock Performance

CC stock traded down $0.6450 during trading on Wednesday, reaching $14.3850. The stock had a trading volume of 1,730,689 shares, compared to its average volume of 3,575,567. The firm has a market cap of $2.15 billion, a PE ratio of -5.13 and a beta of 1.61. The company has a current ratio of 1.68, a quick ratio of 0.83 and a debt-to-equity ratio of 17.16. The stock's 50 day moving average is $12.71 and its two-hundred day moving average is $13.00. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $22.38.

Chemours (NYSE:CC - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.12. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. During the same quarter in the prior year, the business earned $0.38 EPS. The business's quarterly revenue was up 5.0% on a year-over-year basis. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, equities analysts anticipate that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Cuts Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 15th will be issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 15th. Chemours's payout ratio is currently -12.50%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CC. Barclays lowered their price objective on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. UBS Group dropped their target price on Chemours from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Mizuho lifted their price target on Chemours from $13.00 to $16.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Morgan Stanley dropped their price objective on Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a research note on Monday, May 12th. Finally, Wall Street Zen downgraded shares of Chemours from a "hold" rating to a "sell" rating in a research note on Wednesday, May 21st. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Chemours has an average rating of "Moderate Buy" and an average price target of $17.38.

Insider Buying and Selling

In other news, CEO Denise Dignam bought 4,068 shares of Chemours stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average cost of $12.06 per share, with a total value of $49,060.08. Following the acquisition, the chief executive officer owned 191,546 shares of the company's stock, valued at $2,310,044.76. The trade was a 2.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Damian Gumpel purchased 13,400 shares of the company's stock in a transaction on Monday, June 2nd. The stock was purchased at an average price of $9.22 per share, with a total value of $123,548.00. Following the completion of the transaction, the insider owned 123,879 shares of the company's stock, valued at approximately $1,142,164.38. This trade represents a 12.13% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 25,290 shares of company stock valued at $250,437. 0.34% of the stock is currently owned by corporate insiders.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.